All In Biotech

Drug Trial Radar · NCT04530565

Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) in Adults

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 348 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

348

Planned (sponsor's estimate)

Start

Jan 25, 2021

Primary completion

Jul 1, 2028

Study completion Jul 1, 2028

Sponsor

Sponsor type
NIH
First posted
Aug 28, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with the ability of cancer cells to grow and spread. The information gained from this study may help researchers determine if combination therapy with steroids, TKIs, and blinatumomab work better than the standard of care.

Conditions

  • B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

Interventions

  • Biospecimen CollectionProcedure

    Correlative studies

  • BlinatumomabBiological

    Given IV

  • Bone Marrow Aspiration and BiopsyProcedure

    Undergo bone marrow aspiration and biopsy

  • CyclophosphamideDrug

    Given IV

  • CytarabineDrug

    Given IV or IT

  • DasatinibDrug

    Given PO

  • DexamethasoneDrug

    Given PO or IV

  • Doxorubicin HydrochlorideDrug

    Given IV

  • Echocardiography TestProcedure

    Undergo ECHO

  • ElectrocardiographyProcedure

    Undergo ECG

  • Lumbar PunctureProcedure

    Undergo lumbar puncture

  • MesnaDrug

    Given IV

  • MethotrexateDrug

    Given IV or IT

  • Multigated Acquisition ScanProcedure

    Undergo MUGA

  • Ponatinib HydrochlorideDrug

    Given PO

  • PrednisoneDrug

    Given PO

  • Vincristine SulfateDrug

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival (OS)Time frame: Time between randomization and death from any cause, assessed up to 10 years from the date of registration

Locations

211 sites in 3 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama

  • Anchorage Associates in Radiation Medicine

    Anchorage, Alaska

  • Anchorage Radiation Therapy Center

    Anchorage, Alaska

  • Alaska Breast Care and Surgery LLC

    Anchorage, Alaska

  • Alaska Oncology and Hematology LLC

    Anchorage, Alaska

  • Alaska Women's Cancer Care

    Anchorage, Alaska

  • Anchorage Oncology Centre

    Anchorage, Alaska

  • Katmai Oncology Group

    Anchorage, Alaska

  • Providence Alaska Medical Center

    Anchorage, Alaska

  • Mercy Hospital Fort Smith

    Fort Smith, Arkansas

  • Providence Saint Joseph Medical Center/Disney Family Cancer Center

    Burbank, California

  • Community Cancer Institute

    Clovis, California

  • University Oncology Associates

    Clovis, California

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

    Irvine, California

  • UC San Diego Moores Cancer Center

    La Jolla, California

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    Orange, California

  • Yale University

    New Haven, Connecticut

  • Augusta University Medical Center

    Augusta, Georgia

  • Hawaii Cancer Care - Westridge

    ‘Aiea, Hawaii

  • Pali Momi Medical Center

    ‘Aiea, Hawaii

  • Queen's Cancer Center - Pearlridge

    ‘Aiea, Hawaii

  • The Cancer Center of Hawaii-Pali Momi

    ‘Aiea, Hawaii

  • Hawaii Cancer Care Inc - Waterfront Plaza

    Honolulu, Hawaii

  • Queen's Cancer Cenrer - POB I

    Honolulu, Hawaii

  • Queen's Medical Center

    Honolulu, Hawaii

  • Straub Clinic and Hospital

    Honolulu, Hawaii

  • University of Hawaii Cancer Center

    Honolulu, Hawaii

  • Hawaii Cancer Care Inc-Liliha

    Honolulu, Hawaii

  • Kuakini Medical Center

    Honolulu, Hawaii

  • Queen's Cancer Center - Kuakini

    Honolulu, Hawaii

  • The Cancer Center of Hawaii-Liliha

    Honolulu, Hawaii

  • Kapiolani Medical Center for Women and Children

    Honolulu, Hawaii

  • Wilcox Memorial Hospital and Kauai Medical Clinic

    Lihue, Hawaii

  • Saint Luke's Cancer Institute - Boise

    Boise, Idaho

  • Saint Luke's Cancer Institute - Fruitland

    Fruitland, Idaho

  • Saint Luke's Cancer Institute - Meridian

    Meridian, Idaho

  • Saint Alphonsus Cancer Care Center-Nampa

    Nampa, Idaho

  • Saint Luke's Cancer Institute - Nampa

    Nampa, Idaho

  • Saint Luke's Cancer Institute - Twin Falls

    Twin Falls, Idaho

Showing 40 of 211 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.